|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest bearing deposits with banks | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment securities available for sale, at fair value | ||||||||||||||||||||
| Investment securities held to maturity, net of allowance for credit losses | ||||||||||||||||||||
| Total investment securities | ||||||||||||||||||||
| Loans, net of unearned income | ||||||||||||||||||||
| Less: Allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Restricted stock | ||||||||||||||||||||
| Bank owned life insurance (BOLI) | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Other real estate owned (OREO) | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| FHLBNY borrowings | ||||||||||||||||||||
| Subordinated debentures | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' Equity | ||||||||||||||||||||
| Preferred stock, 1,000,000 shares authorized, $1,000 liquidation value Series B non-cumulative convertible; 325 shares outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.10 par value; authorized 15,000,000 shares; Issued: 12,545,792 shares and 12,425,768 shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, 784,522 shares at June 30, 2026 and December 31, 2025, at cost | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
